Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Ligand Pharmaceuticals completed a $15 million investment tranche in Orchestra BioMed, bringing total capital deployed under the royalty financing agreement to $40 million. The funding is royalty-based and supports Orchestra BioMed's ongoing pivotal trials for AVIM Therapy and Virtue SAB.
Key figures
- Deal Value Usd
- 15000000
- Medtronic investment
- 20000000
- Total capital from ligand
- 40000000
- Total strategic capital may 1
- 35000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.